As a result, GLP-1-based therapeutics including GLP-1R agonists, have become an important part of improving glycemia for individuals with chronic metabolic diseases such as obesity and Type 2 Diabetes (T2D) [5]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.